Christopher S. Bral, Ph.D.

Vice President, Nonclinical Development
Christopher S. Bral, Ph.D. joined Omeros as our vice president, nonclinical development in October 2015. From April 2014 to October 2015, Dr. Bral was the executive director, toxicology at Arrowhead Research Corporation. From June 2008 to April 2014, Dr. Bral served as director, drug safety evaluation at Vertex Pharmaceuticals. Prior to Vertex, Dr. Bral held various pre-clinical drug safety positions of increasing responsibility at Schering-Plough Research Institute including associate director, drug safety evaluation. Dr. Bral received his Ph.D. in Biochemistry and Biophysics from Texas A&M University and his B.S. in Chemistry from John Carroll University, and has been board-certified in toxicology through the American Board of Toxicology since 2000.